Literature DB >> 14555889

European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts).

Guy De Backer1, Ettore Ambrosioni, Knut Borch-Johnsen, Carlos Brotons, Renata Cifkova, Jean Dallongeville, Shah Ebrahim, Ole Faergeman, Ian Graham, Giuseppe Mancia, Volkert Manger Cats, Kristina Orth-Gomér, Joep Perk, Kalevi Pyörälä, José L Rodicio, Susana Sans, Vedat Sansoy, Udo Sechtem, Sigmund Silber, Troels Thomsen, David Wood.   

Abstract

Guidelines aim to present all the relevant evidence on a particular issue in order to help physicians to weigh the benefits and risks of a particular diagnostic or therapeutic procedure. They should be helpful in everyday clinical decision-making. A great number of guidelines have been issued in recent years by different organisations--European Society of Cardiology (ESC), American Heart Association (AHA), American College of Cardiology (ACC), and other related societies. By means of links to web sites of National Societies several hundred guidelines are available. This profusion can put at stake the authority and validity of guidelines, which can only be guaranteed if they have been developed by an unquestionable decision-making process. This is one of the reasons why the ESC and others have issued recommendations for formulating and issuing guidelines. In spite of the fact that standards for issuing good quality guidelines are well defined, recent surveys of guidelines published in peer-reviewed journals between 1985 and 1998 have shown that methodological standards were not complied with in the vast majority of cases. It is therefore of great importance that guidelines and recommendations are presented in formats that are easily interpreted. Subsequently, their implementation programmes must also be well conducted. Attempts have been made to determine whether guidelines improve the quality of clinical practice and the utilisation of health resources. In addition, the legal implications of medical guidelines have been discussed and examined, resulting in position documents, which have been published by a specific task force. The ESC Committee for practice guidelines (CPG) supervises and coordinates the preparation of new guidelines and expert consensus documents produced by task forces, expert groups or consensus panels. The Committee is also responsible for the endorsement of these guidelines or statements.

Entities:  

Mesh:

Year:  2003        PMID: 14555889     DOI: 10.1097/01.hjr.0000087913.96265.e2

Source DB:  PubMed          Journal:  Eur J Cardiovasc Prev Rehabil        ISSN: 1741-8267


  141 in total

1.  Randomized controlled trial on the long-term efficacy of a multifaceted, interdisciplinary lifestyle intervention in reducing cardiovascular risk and improving lifestyle in patients at risk of cardiovascular disease.

Authors:  Lysanne Goyer; Robert Dufour; Caroline Janelle; Chantal Blais; Christine L'Abbé; Emilie Raymond; Jacques de Champlain; Pierre Larochelle
Journal:  J Behav Med       Date:  2012-03-09

2.  Cardiovascular risk management of hypertension and hypercholesterolaemia in the Netherlands: from unifactorial to multifactorial approach.

Authors:  I van Dis; J M Geleijnse; W M M Verschuren; D Kromhout
Journal:  Neth Heart J       Date:  2012-08       Impact factor: 2.380

3.  Behavioral interventions for coronary heart disease patients.

Authors:  Kristina Orth-Gomér
Journal:  Biopsychosoc Med       Date:  2012-02-02

4.  Nutrition, environment and cardiovascular health (NESCAV): protocol of an inter-regional cross-sectional study.

Authors:  Ala'a Alkerwi; Michèle Guillaume; Faiez Zannad; Ulrich Laufs; Marie-Lise Lair
Journal:  BMC Public Health       Date:  2010-11-15       Impact factor: 3.295

5.  Implementation of Cardiovascular Disease Prevention Guidelines in Clinical Practice-Can We Do Better?

Authors:  Kornelia Kotseva
Journal:  Curr Treat Options Cardiovasc Med       Date:  2015-12

6.  Impact of high dose statin trials on hospital prescribers.

Authors:  Thomas I Barron; Kathleen Bennett; John Feely
Journal:  Eur J Clin Pharmacol       Date:  2006-11-18       Impact factor: 2.953

7.  Gender-specific association of psychological distress with cardiovascular risk scores.

Authors:  Pekka Johannes Puustinen; Hannu Koponen; Hannu Kautiainen; Pekka Mäntyselkä; Mauno Vanhala
Journal:  Scand J Prim Health Care       Date:  2010-03       Impact factor: 2.581

8.  Coronary risk equivalence of diabetes assessed by SPECT-MPI.

Authors:  Donna Chelle V Morales; Sanjeev P Bhavnani; Alan W Ahlberg; Raja C Pullatt; Deborah M Katten; Donna M Polk; Gary V Heller
Journal:  J Nucl Cardiol       Date:  2017-12-06       Impact factor: 5.952

9.  Estimating the high risk group for cardiovascular disease in the Norwegian HUNT 2 population according to the 2003 European guidelines: modelling study.

Authors:  Linn Getz; Johann A Sigurdsson; Irene Hetlevik; Anna Luise Kirkengen; Solfrid Romundstad; Jostein Holmen
Journal:  BMJ       Date:  2005-08-15

10.  Lack of a pharmacokinetic interaction between a new smoking cessation therapy, varenicline, and digoxin in adult smokers.

Authors:  H M Faessel; A H Burstein; M D Troutman; S A Willavize; K D Rohrbacher; D J Clark
Journal:  Eur J Clin Pharmacol       Date:  2008-07-26       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.